BioCryst Pharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the Biocrist First Quarter 2021 Earnings Call. Please note that today's call is being recorded. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask your question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker for today, John Bluth at Biocrist. John, the floor is yours.

Thanks, Jay. Good morning and welcome to Biocrist's first quarter 2021 corporate update and financial results conference call. Today's press release is available on our website. Participating with me today are CEO John Stonehouse, CFO Anthony Doyle, Chief Commercial Officer Charlie Geyer, Chief Medical Officer Dr. Bill Sheridan, Chief Business Officer Megan Stasinski, and Chief R&D Officer Dr. Helen Thackray. Following our remarks, we will answer your questions. Before we begin, please note that today's conference call will contain forward-looking statements, including those statements regarding future results on audited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties, which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. You should not place undue reliance on these forward-looking statements. For additional information, including a detailed discussion of our risk factors, please refer to the company's documents filed with the Securities and Exchange Commission, which can be accessed on our website. I'd now like to turn the call over to John Stonehouse.

Thanks, John. I couldn't be more excited to have our first earnings call with revenue from a Biochrist launch product. This is the latest evidence that our company is going through a major transformation. Sales were very encouraging in Q1, especially considering this is our first quarter of the launch of Hortodeo. This is a direct result of focused execution of our plan by the Biochrist team, and the desire to build a great company that can discover, develop, and now successfully commercialize oral medicines for patients suffering from rare diseases. Very few companies can do all three. The launch is off to a great start because we have a great drug. It works. Patients are experiencing meaningful reductions in their attacks, and they can achieve this by taking one capsule once a day. This is leading to patient switches from injectable protein on-demand therapy. It's exactly what we saw in our market research and clinical trials, and it's already playing out in the marketplace. Great drugs don't sell themselves. We also have a fantastic team. Charlie and Alan Hodge, our USGM, have assembled an experienced team, but more importantly, they're working together, working through challenges and obstacles like COVID and achieving great results. We couldn't be more pleased with the start, and the good news, we're just getting going with so many more patients to reach in the U.S. While the U.S. is the largest market, we now have approval in other major territories around the world. Our partner, Tori, is launching in Japan, and we recently received approval in the EU. The same planning and investments were made here, too. The launch ramp will take longer, as these are different markets from the U.S., But we expect these countries to contribute over time to our goal of achieving $500 million plus in global peak sales. And finally, our pipeline is full with the opportunity we have with our oral factor D inhibitor, BCX9930, for patients suffering from many different complement-mediated rare diseases. We're heading into pivotal studies in PNH and proof-of-concept in nephritis indications. We will apply all the learnings of our HAE program and build off that success to bring 9930 to market to create even greater value as a company that discovers, develops, and commercializes multiple oral drugs for patients suffering from rare diseases. Now I'll turn the call over to Charlie to go over more details about our early launch success. Charlie?